tetano
Editor, Senior Moderator
Sci Rep
. 2024 Nov 28;14(1):29634.
doi: 10.1038/s41598-024-81028-3. Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
Panpan Liang[SUP] #[/SUP][SUP] 1 [/SUP], Yan Li[SUP] #[/SUP][SUP] 2 [/SUP], Li'e Meng[SUP] 1 [/SUP], Yuting Li[SUP] 3 [/SUP], Hailing Mai[SUP] 4 [/SUP], Tao Li[SUP] 1 [/SUP], Jiarui Ma[SUP] 1 [/SUP], Junhui Ma[SUP] 1 [/SUP], Jing Wang[SUP] 3 [/SUP], Bing Zhuan[SUP] 5 [/SUP], Wei Zhou[SUP] 6 [/SUP]
Affiliations
Baseline IL-6 levels have been found to be non-predictive of subsequent outcomes following tocilizumab treatment, highlighting the need for more reliable predictive markers. To address this, a retrospective analysis was conducted on the clinical profiles, diagnostic tests, and follow-up prognoses of 60 patients with severe or critical COVID-19, all of whom were identified as experiencing a cytokine storm and subsequently received tocilizumab treatment. Among the patients, the overall survival rate during follow-up was 80%, with further analysis revealing that advanced age was an independent risk factor for adverse outcomes. Following tocilizumab administration, a statistically significant increase in IL-6 and D-dimer levels was observed, while markers such as C-reactive protein (CRP), procalcitonin (PCT), and fibrinogen demonstrated reductions compared to pre-treatment values. Specifically, IL-6 levels initially surged briefly after tocilizumab intervention before gradually diminishing. To assess the prognostic utility of IL-6, the Receiver Operating Characteristic (ROC) curve was employed, which yielded an area under the curve (AUC) of 0.812, indicating strong predictive capability, with a sensitivity of 100% and a specificity of 53.49%. The optimal cut-off value for IL-6 was identified at 147.79 pg/mL. In conclusion, IL-6 levels tend to rise transiently following tocilizumab therapy, before gradually declining. These post-treatment IL-6 measurements may serve as a valuable biomarker for assessing prognosis in patients undergoing this treatment.
Keywords: COVID-19; IL6; Prognosis; Tocilizumab.
. 2024 Nov 28;14(1):29634.
doi: 10.1038/s41598-024-81028-3. Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
Panpan Liang[SUP] #[/SUP][SUP] 1 [/SUP], Yan Li[SUP] #[/SUP][SUP] 2 [/SUP], Li'e Meng[SUP] 1 [/SUP], Yuting Li[SUP] 3 [/SUP], Hailing Mai[SUP] 4 [/SUP], Tao Li[SUP] 1 [/SUP], Jiarui Ma[SUP] 1 [/SUP], Junhui Ma[SUP] 1 [/SUP], Jing Wang[SUP] 3 [/SUP], Bing Zhuan[SUP] 5 [/SUP], Wei Zhou[SUP] 6 [/SUP]
Affiliations
- PMID: 39609511
- PMCID: PMC11605089
- DOI: 10.1038/s41598-024-81028-3
Baseline IL-6 levels have been found to be non-predictive of subsequent outcomes following tocilizumab treatment, highlighting the need for more reliable predictive markers. To address this, a retrospective analysis was conducted on the clinical profiles, diagnostic tests, and follow-up prognoses of 60 patients with severe or critical COVID-19, all of whom were identified as experiencing a cytokine storm and subsequently received tocilizumab treatment. Among the patients, the overall survival rate during follow-up was 80%, with further analysis revealing that advanced age was an independent risk factor for adverse outcomes. Following tocilizumab administration, a statistically significant increase in IL-6 and D-dimer levels was observed, while markers such as C-reactive protein (CRP), procalcitonin (PCT), and fibrinogen demonstrated reductions compared to pre-treatment values. Specifically, IL-6 levels initially surged briefly after tocilizumab intervention before gradually diminishing. To assess the prognostic utility of IL-6, the Receiver Operating Characteristic (ROC) curve was employed, which yielded an area under the curve (AUC) of 0.812, indicating strong predictive capability, with a sensitivity of 100% and a specificity of 53.49%. The optimal cut-off value for IL-6 was identified at 147.79 pg/mL. In conclusion, IL-6 levels tend to rise transiently following tocilizumab therapy, before gradually declining. These post-treatment IL-6 measurements may serve as a valuable biomarker for assessing prognosis in patients undergoing this treatment.
Keywords: COVID-19; IL6; Prognosis; Tocilizumab.